Melanocyte-Targeting Protein Nanocages for Hyperpigmentation Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hyperpigmentation disorders, such as melasma, suffer from complications like irritation, depigmentation, and untargeted drug delivery, leading to side effects and reduced efficacy.
Innovation Solution
Development of melanocyte-targeting protein nanocages functionalized with melanocyte-targeting moieties and skin penetrating/cell permeating moieties, allowing for targeted delivery of therapeutic and diagnostic agents to melanocytes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topical treatments are used to inhibit tyrosinase enzymes for melanin biosynthesis, then hyperpigmentation disorders can be treated, but complications such as irritation, depigmentation, and allergic contact dermatitis occur due to untargeted drug delivery
Solution Approach 1:
The patent uses protein nanocages as intermediary carriers to deliver tyrosinase inhibitors specifically to melanocytes. The nanocages are functionalized with targeting moieties that bind to melanocyte surface receptors, enabling selective drug delivery to the intended target cells while avoiding healthy skin tissues, thus reducing side effects like irritation and allergic contact dermatitis
Solution Approach 2:
The invention implements local quality by functionalizing the nanocage surface with specific targeting moieties (such as peptides or antibodies) that recognize and bind to melanocyte-specific receptors. This creates a localized targeting capability where the therapeutic agent is delivered only to melanocytes in the affected areas, preventing systemic or non-specific effects on healthy skin
2Adaptability or versatility
If untargeted drug delivery is used for treating hyperpigmentation, then treatment can be applied broadly, but specificity is reduced leading to depigmentation and other complications
Solution Approach 1:
The protein nanocage serves as a mediator between the therapeutic agent and the target cells. The nanocage is engineered with dual functionality: it carries the tyrosinase inhibitor payload and displays targeting moieties on its surface that specifically recognize melanocytes, thus achieving both broad treatment capability and high targeting precision
Solution Approach 2:
The invention changes the physical and chemical parameters of the drug delivery system by using nanoscale protein cages with controlled size, charge, and surface properties. These parameter optimizations enable the nanocages to penetrate skin barriers effectively while maintaining high affinity binding to melanocyte receptors, achieving both broad applicability and precise targeting
Data Source
AI summary
The present invention relates to protein nanocages comprising a melanocyte-targeting moiety and pharmaceutical compositions comprising the protein cages as well as methods for treating or diagnosing hyperpigmentation disorders or other melanocyte-related disorders using the protein nanocages or pharmaceutical compositions.